# Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study).

> **NCT05720130** · PHASE1,PHASE2 · RECRUITING · sponsor: **AdvanCell Pty Limited** · enrollment: 100 (estimated)

## Conditions studied

- Prostate Cancer
- Metastatic Castration-resistant Prostate Cancer
- Metastatic Hormone Sensitive Prostate Cancer

## Interventions

- **DRUG:** [²¹²Pb]Pb-ADVC001 (Phase 1b)
- **DRUG:** [²¹²Pb]Pb-ADVC001 (Phase 2a)

## Key facts

- **NCT ID:** NCT05720130
- **Lead sponsor:** AdvanCell Pty Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-15
- **Primary completion:** 2029-01-31
- **Final completion:** 2029-06-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05720130

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05720130, "Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study).". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05720130. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*